Calcium sensitization in perfused beating guinea pig heart by a positive inotropic agent MCI-154. 1996

Y Abe, and R Ishisu, and K Onishi, and K Sekioka, and A Narimatsu, and T Nakano
First Department of Internal Medicine, Mie University School of Medicine, Tsu, Japan.

We investigated the effects of MCI-154, a positive inotropic agent that increases the myofilament response to Ca++, on Ca++ transients, left ventricular (LV) function and phosphodiesterase (PDE) III activity of guinea pig heart, and compared them with the effects of pimobendan and milrinone. In Langendorff guinea pig hearts loaded with a fluorescent Ca++ probe indo-1, LV pressure and Ca++ transient were measured simultaneously. MCI-154 (10(-10)-10(-6) M) increased LV developed pressure, +dP/dt and -dP/dt with a reduction of LV end-diastolic pressure, although it did not affect coronary flow. The positive inotropic activity of MCI-154 was more potent than that of pimobendan and milrinone; EC50 values (concentrations for increasing +dP/dt by 50% from base line) were 4.31, 41.5 and 294 x 10(-9) M, respectively. The positive inotropic effect of MCI-154 was accompanied by the increase in systolic, diastolic and amplitude of indo-1 fluorescence ratio. The relative increase in Ca++ transients against the increase in LV contractility produced by MCI-154, however, was significantly less than that by increasing perfusate [Ca++], pimobendan or milrinone. MCI-154 (3 x 10(-7)-10(-4) M) inhibited the activity of PDE III isolated from guinea pig LV tissues, but the inhibitory effect of MCI-154 was less than pimobendan and milrinone; IC50 values were 10.1, 3.5 and 2.4 x 10(-6) M, respectively. These findings suggest that MCI-154 exerts a positive inotropic effect mainly through Ca(++)-sensitizing action in intact beating whole hearts.

UI MeSH Term Description Entries
D007211 Indoles Benzopyrroles with the nitrogen at the number one carbon adjacent to the benzyl portion, in contrast to ISOINDOLES which have the nitrogen away from the six-membered ring.
D008297 Male Males
D009206 Myocardium The muscle tissue of the HEART. It is composed of striated, involuntary muscle cells (MYOCYTES, CARDIAC) connected to form the contractile pump to generate blood flow. Muscle, Cardiac,Muscle, Heart,Cardiac Muscle,Myocardia,Cardiac Muscles,Heart Muscle,Heart Muscles,Muscles, Cardiac,Muscles, Heart
D010477 Perfusion Treatment process involving the injection of fluid into an organ or tissue. Perfusions
D010726 Phosphodiesterase Inhibitors Compounds which inhibit or antagonize the biosynthesis or actions of phosphodiesterases. Phosphodiesterase Antagonists,Phosphodiesterase Inhibitor,Phosphoric Diester Hydrolase Inhibitors,Antiphosphodiesterases,Inhibitor, Phosphodiesterase
D011724 Pyridazines Six-membered rings with two adjacent nitrogen atoms also called 1,2-diazine.
D011728 Pyridones Pyridine derivatives with one or more keto groups on the ring. Pyridinones
D002118 Calcium A basic element found in nearly all tissues. It is a member of the alkaline earth family of metals with the atomic symbol Ca, atomic number 20, and atomic weight 40. Calcium is the most abundant mineral in the body and combines with phosphorus to form calcium phosphate in the bones and teeth. It is essential for the normal functioning of nerves and muscles and plays a role in blood coagulation (as factor IV) and in many enzymatic processes. Coagulation Factor IV,Factor IV,Blood Coagulation Factor IV,Calcium-40,Calcium 40,Factor IV, Coagulation
D002316 Cardiotonic Agents Agents that have a strengthening effect on the heart or that can increase cardiac output. They may be CARDIAC GLYCOSIDES; SYMPATHOMIMETICS; or other drugs. They are used after MYOCARDIAL INFARCT; CARDIAC SURGICAL PROCEDURES; in SHOCK; or in congestive heart failure (HEART FAILURE). Cardiac Stimulant,Cardiac Stimulants,Cardioprotective Agent,Cardioprotective Agents,Cardiotonic,Cardiotonic Agent,Cardiotonic Drug,Inotropic Agents, Positive Cardiac,Myocardial Stimulant,Myocardial Stimulants,Cardiotonic Drugs,Cardiotonics,Agent, Cardioprotective,Agent, Cardiotonic,Drug, Cardiotonic,Stimulant, Cardiac,Stimulant, Myocardial
D005453 Fluorescence The property of emitting radiation while being irradiated. The radiation emitted is usually of longer wavelength than that incident or absorbed, e.g., a substance can be irradiated with invisible radiation and emit visible light. X-ray fluorescence is used in diagnosis.

Related Publications

Y Abe, and R Ishisu, and K Onishi, and K Sekioka, and A Narimatsu, and T Nakano
June 1993, Journal of cardiovascular pharmacology,
Y Abe, and R Ishisu, and K Onishi, and K Sekioka, and A Narimatsu, and T Nakano
March 1990, Critical care medicine,
Y Abe, and R Ishisu, and K Onishi, and K Sekioka, and A Narimatsu, and T Nakano
July 1990, Journal of cardiovascular pharmacology,
Y Abe, and R Ishisu, and K Onishi, and K Sekioka, and A Narimatsu, and T Nakano
November 1987, The Journal of pharmacology and experimental therapeutics,
Y Abe, and R Ishisu, and K Onishi, and K Sekioka, and A Narimatsu, and T Nakano
October 1995, Journal of cardiovascular pharmacology,
Y Abe, and R Ishisu, and K Onishi, and K Sekioka, and A Narimatsu, and T Nakano
April 1996, Journal of cardiovascular pharmacology,
Y Abe, and R Ishisu, and K Onishi, and K Sekioka, and A Narimatsu, and T Nakano
May 2000, Journal of cardiovascular pharmacology,
Y Abe, and R Ishisu, and K Onishi, and K Sekioka, and A Narimatsu, and T Nakano
May 1986, European journal of pharmacology,
Y Abe, and R Ishisu, and K Onishi, and K Sekioka, and A Narimatsu, and T Nakano
October 1994, Journal of cardiovascular pharmacology,
Y Abe, and R Ishisu, and K Onishi, and K Sekioka, and A Narimatsu, and T Nakano
August 1987, Japanese journal of pharmacology,
Copied contents to your clipboard!